CD33 and breast cancer: Cancer cell-derived IL-6 activates the STAT3 pathway in MDSCs, subsequently upregulating indoleamine 2,3-dioxygenase in co-cultures of human CD33(+) myeloid progenitors with MDA-MB-231 breast cancer cells [141].